lopinavir has been researched along with Infections, Coronavirus in 245 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (3.27) | 24.3611 |
| 2020's | 237 (96.73) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D | 1 |
| Chen, J; Cheng, Q; Fang, Z; Jia, Q; Zhao, G | 1 |
| Billinge, SJL; Culbertson, E; Ferreira, FF; Lima Barros de Araujo, G; Moreira Pinheiro, LB; Tao, S | 1 |
| Abdullah, ML; Al Faraj, S; Al Harbi, S; Al Jeraisy, M; Al Mekhlafi, GA; Al-Dawood, A; Alharbi, NK; Aljami, HA; AlJohani, S; AlMutairi, BM; Arabi, YM; Asiri, AY; Assiri, AM; Balkhy, HH; Deeb, AM; Elzein, FE; Fowler, RA; Ghazal, S; Hayden, FG; Jokhdar, HAA; Jose, J; Mandourah, Y; Memish, ZA; Sherbeeni, NM | 1 |
| Abdelzaher, M; Al Bshabshe, A; Al Faraj, S; Al Harbi, S; Al Harthy, A; Al Jeraisy, M; Al Mekhlafi, GA; Al Sulaiman, M; Al-Dawood, A; Al-Hameed, F; AlJohani, S; Almotairi, A; Alothman, A; AlSaedi, A; Arabi, YM; Asiri, AY; Assiri, AM; Aziz Jokhdar, HA; Bajhmom, W; Balkhy, HH; Deeb, AM; Elzein, FE; Fowler, RA; Ghazal, S; Hayden, FG; Hussein, MA; Jose, J; Kharaba, A; Kojan, S; Mady, A; Mandourah, Y; Memish, ZA; Sherbeeni, NM | 1 |
| Babusis, D; Baric, RS; Bauer, L; Brown, AJ; Cihlar, T; Clarke, MO; Denison, MR; Feng, JY; Hogg, A; Jordan, R; Leist, SR; Montgomery, SA; Porter, D; Schäfer, A; Sellers, S; Sheahan, TP; Sims, AC; Spahn, JE; Won, J | 1 |
| Lu, H | 1 |
| Chen, F; Chen, X; Lu, Y; Wang, Z; Zhang, W | 1 |
| Choe, KW; Jeon, S; Kang, YM; Kim, MJ; Lee, B; Lee, WJ; Lim, J; Park, SJ; Seong, YM; Shin, HY | 2 |
| Maxmen, A | 1 |
| Kim, JY | 1 |
| Qian, JD; Wang, GQ; Wang, Y; Yao, TT; Zhu, WY | 1 |
| Huang, P; Tao, G; Yang, GN; Zhang, YW; Zheng, XW | 1 |
| Anderson, DE; Ang, LW; Chan, KS; Chan, M; Chen, MI; Cui, L; Kalimuddin, S; Kurupatham, L; Lau, SK; Lee, VJM; Leo, YS; Lin, RTP; Loh, J; Low, JG; Lye, DC; Mak, TM; Marimuthu, K; Ng, OT; Ng, TY; Ong, SWX; Said, Z; Tan, BH; Tan, SY; Tan, TY; Vasoo, S; Wang, LF; Young, BE | 1 |
| Huang, Y; Xie, C; Zhang, H | 1 |
| Chen, YK; Harypursat, V; He, XQ; Huang, YQ; Li, Y; Tang, SQ; Xu, XL; Zeng, YM | 1 |
| Martinez, MA | 2 |
| Cao, Y; Xu, S; Zhou, M; Zhu, F | 1 |
| Chen, Q; Dai, Y; Gao, G; Han, W; Li, J; Li, L; Li, X; Liu, C; Quan, B; Wang, C; Yang, J; Zhang, G; Zhang, J; Zhang, Z; Zheng, W | 1 |
| Cao, B; Li, H; Wang, YM; Xu, JY | 1 |
| Du, B; Kang, HYJ; Li, XY; Qiu, HB; Sun, B; Tong, ZH; Wang, F; Wang, YS; Zhan, X | 1 |
| Wang, Y; Zhu, LQ | 1 |
| Deng, L; Hong, Z; Li, C; Li, X; Liu, X; Xia, J; Zeng, Q; Zhang, H | 1 |
| Liu, F; Pan, K; Xu, A; Xuan, W; Yan, T; Yu, W; Zhang, J; Zhang, Y | 1 |
| Li, L; Liu, L; Liu, Y; Luo, N; Wang, X; Wang, Y | 1 |
| Baden, LR; Rubin, EJ | 1 |
| Bai, T; Cai, Y; Cao, B; Chen, H; Chen, N; Cheng, F; Dong, C; Dong, X; Fan, G; Ge, Q; Gong, F; Gu, X; Guo, L; Hayden, FG; He, J; Horby, PW; Hu, X; Huang, C; Huang, H; Jaki, T; Jia, C; Li, C; Li, H; Li, K; Li, X; Liu, W; Liu, X; Liu, Y; Liu, Z; Lu, S; Luo, S; Pan, L; Peng, L; Qiu, F; Qu, Z; Ruan, L; Ruan, S; Shang, L; Song, B; Tu, S; Wang, C; Wang, J; Wang, K; Wang, S; Wang, Y; Wei, M; Wei, Y; Wen, D; Wu, J; Wu, X; Xia, J; Xiang, J; Xie, X; Xu, J; Yu, T; Yuan, Y; Zhan, H; Zhang, D; Zhang, L; Zhang, Y; Zhou, F; Zhou, X; Zou, J | 1 |
| Baden, LR; Morrissey, S; Rubin, EJ | 2 |
| Duan, Y; Zhou, C; Zhu, HL | 1 |
| Fang, W; Hu, Y; Huang, D; Huang, G; Huang, X; Lang, C; Li, B; Luo, Y; Lv, J; Shen, L; Sun, Q; Wan, S; Xiang, Y; Xiong, Y; Yang, H; Yang, R; Zheng, Y | 1 |
| Cohen, J; Kupferschmidt, K | 1 |
| Ding, X; Kou, S; Lan, J; Li, X; Liang, Y; Liu, L; Liu, Y; Pan, Y; Tan, G; Tang, S; Wang, Z; Yuan, J; Zeng, L; Zou, R | 1 |
| Cravedi, P; Degli Antoni, A; Delsante, M; Fiaccadori, E; Gandolfini, I; Maggiore, U; Manenti, L; Peruzzi, L; Riella, LV; Zaza, G | 1 |
| Hong, W | 1 |
| Chen, B; Chen, H; Hong, Z; Huang, M; Jiang, S; Kong, L; Li, M; Liang, J; Lu, J; Ma, R; Pang, P; Pei, D; Qin, D; Shan, H; Shu, J; Tang, T; Xia, J; You, Y | 1 |
| Chang, YL; Chen, MY; Lee, WS; Lu, CC | 1 |
| Chan, MCW; Chen, D; Cheung, PP; Choy, KT; Chu, DKW; Huang, X; Hui, KPY; Kaewpreedee, P; Peiris, M; Sia, SF; Wong, AY; Yen, HL | 1 |
| Barlow, A; Barlow, B; Claassen, CW; Heavner, JJ; Heavner, MS; Landolf, KM; Yeung, SYA | 1 |
| Al-Tawfiq, JA; Memish, ZA | 1 |
| Chen, W; Ding, JG; Du, WJ; Hong, L; Luo, YL; Ruan, ZW; Sun, QF; Wang, XF; Xia, SC; Ye, XT; Zhang, WW; Zhou, Y | 1 |
| Stower, H | 1 |
| Dong, CF; Feng, C; Gao, H; Li, JX; Li, YJ; Liu, L; Liu, YX; Wang, FX; Wang, LF; Wang, Y; Wu, WB; Xie, XJ; Yuan, J; Zeng, JH | 1 |
| Li, L; Li, W; Liu, H; Liu, L; Nashan, B; Ning, L; Shen, A; Wang, J; Yao, Z; Zhang, S; Zhao, D | 1 |
| Bagalà, A; Bartiromo, M; Bartoloni, A; Borchi, B; Botta, A; Bresci, S; Cavallo, A; Cirami, C; Cutruzzulà, R; Larti, A; Lugli, G; Tilli, M; Vaglio, A; Xhaferi, B | 1 |
| Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM | 1 |
| Chen, C; Lu, J; Lu, Z; Xu, T; Xue, Y; Yang, G; Zha, T; Zhu, Z | 1 |
| Chen, L; Cheng, J; Cheng, X; Fan, Z; Huang, S; Li, J; Liu, Z; Tian, C; Yang, J; Zhang, Y | 1 |
| Calmy, A; Doherty, M; Ford, N; Norris, SL; Rangaraj, A; Vitoria, M | 1 |
| Şimşek Yavuz, S; Ünal, S | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Costanzo, M; De Giglio, MAR; Roviello, GN | 1 |
| Doan, T; Oldenburg, CE | 1 |
| Aguado, JM; Andrés, A; Delgado, JF; Fernández-Ruiz, M; Folgueira, MD; González, E; Lalueza, A; Loinaz, C; López-Medrano, F; Lumbreras, C; Polanco, N; San Juan, R | 1 |
| Del Popolo, G; Righi, G | 1 |
| Mullard, A | 1 |
| Hsueh, PR; Jean, SS; Lee, PI | 1 |
| Choi, SW; Kang, S; Lee, S; Lim, DH; Seo, KW; So, MW; Song, J | 1 |
| Hamabe, Y; Hikone, M; Ishida, T; Kobayashi, M; Kuwahara, Y; Nakamura, K; Sakamoto, N; Shimizu, H; Sugiyama, K; Tanabe, M; Washino, T | 1 |
| Aryal, D; Beane, A; Dondorp, AM; Hayat, M; Schultz, MJ | 1 |
| Bernacchia, D; Cattaneo, D; Conti, F; Gervasoni, C; Lupo, A; Merli, S; Pezzati, L; Riva, A; Rusconi, S; Siano, M; Sollima, S | 1 |
| Feng, X; Jiang, Y; Liu, C; Qu, F; Xi, H; Zhao, X; Zhao, Y | 1 |
| Betti, M; Danzi, GB; Dellanoce, C; Giorgi-Pierfranceschi, M; Morandini, R; Palareti, G; Pan, A; Paoletti, O; Prandoni, P; Tala, M; Testa, S | 1 |
| Chen, CP; Cheng, CY; Cheng, SH; Lee, YL; Liao, CH; Lin, YC; Liu, CE | 1 |
| Ahsan, W; Alhazmi, HA; Bratty, MA; Javed, S; Najmi, A | 1 |
| Alwayn, IPJ; de Fijter, JW; de Vries, APJ; Janson, JA; Meziyerh, S; Moes, DJAR; Reinders, MEJ; van Etten, RW; van Gelder, T; Zwart, TC | 1 |
| Han, S; Hyun, M; Jin, K; Kim, HA; Kim, Y; Kwon, O; Lee, JY; Paek, JH; Park, WY | 1 |
| Dhochak, N; Kabra, SK; Lodha, R; Sankar, J | 1 |
| Wan, Y; Wang, D; Wu, F; Zhang, L; Zhang, W | 1 |
| Ardura, M; Auletta, JJ; Dandoy, C; Hartley, D; Jaglowski, S; Lehmann, L | 1 |
| Ackerman, MJ; Friedman, PA; Giudicessi, JR; Noseworthy, PA | 1 |
| Jiang, J; Lin, S; Ruan, J; Wang, L; Xu, X; Ye, H | 1 |
| Delang, L; Neyts, J | 1 |
| Daneshpazhooh, M; Isazade, A; Noormohammadpour, P; Soori, T | 1 |
| Dalerba, P; Levin, B; Thompson, JL | 1 |
| Kunz, KM | 1 |
| Havlichek, D | 1 |
| Cacopardo, B; Corrao, S; Natoli, G | 1 |
| Carmona-Bayonas, A; Castañón, E; Jimenez-Fonseca, P | 1 |
| Cao, B; Wang, C; Zhang, D | 1 |
| Azzari, C; Bortone, B; Casini, T; Favre, C; Galli, L; Moriondo, M; Pegoraro, F; Sieni, E; Tondo, A | 1 |
| Chen, X; Chen, Y; Dhuromsingh, M; Fang, F; Huang, Y; Jiao, R; Li, H; Li, Y; Luo, X; Ning, Q; Qiu, L; Sun, Z; Tian, N; Xu, R; Zeng, F; Zhang, A; Zhang, Y | 1 |
| Chen, L; Chen, Q; Huang, Y; Lin, H; Wu, Y; Xie, Q; Zhu, Y | 1 |
| Ahn, JH; Choi, EY; Chung, JH; Hong, KS; Jang, JG; Jin, HJ; Lee, KH; Lee, W; Shin, KC | 1 |
| Coumou, J; de Vries, PJ | 1 |
| Besutti, G; Bonacini, R; Dolci, G; Guaraldi, G; Iotti, V; Ligabue, G; Maiorana, M; Marini, G; Massari, M; Monelli, F; Pattacini, P; Riva, N; Rossi, PG; Spaggiari, L | 1 |
| Chan, JMC; Chik, TSH; Choi, CYC; Lau, AWT; Lau, DPL; Leung, WS; Tsang, OTY | 1 |
| Gadebusch Bondio, M; Marloth, M | 1 |
| Anastasiou, IA; Eleftheriadou, I; Tentolouris, A; Tentolouris, N; Tsilingiris, D | 1 |
| Wang, Y; Xia, T | 1 |
| Shalhoub, S | 1 |
| Chan, J; Chan, JF; Chan, JW; Chan, KH; Chan, V; Chan, WM; Cheng, VC; Chu, AW; Chu, MY; Chung, TW; Fung, AY; Fung, K; Hung, IF; Ip, JD; Lau, CS; Law, WL; Lee, R; Leung, KH; Leung, WS; Lie, AK; Liu, R; Lo, J; Lung, DC; Lung, KC; Ng, AC; Ng, YY; Que, TL; Shum, HP; Sin, KM; Sin, S; Tam, AR; To, KK; Tsang, OT; Tso, EY; Wu, AK; Wu, TC; Yan, EY; Yan, WW; Yeung, A; Yeung, P; Yip, CC; Yuen, KY; Zhang, RR | 1 |
| Anselmi, E; Cavanna, L; Citterio, C; Codeluppi, M; Stroppa, EM; Toscani, I; Zaffignani, E | 1 |
| Baldelli, S; Cattaneo, D; Clementi, E; Corbellino, M; Gervasoni, C | 1 |
| Abolhassani, H; Baldanti, F; Hammarström, L; Marcotte, H; Pan-Hammarström, Q | 1 |
| Canali, E; Cavallieri, F; Fasano, A; Valzania, F | 1 |
| Andini, R; Bertolino, L; Corcione, A; Durante-Mangoni, E; Florio, LL; Mele, F; Murino, P; Zampino, R | 1 |
| Ashton, NJ; Blennow, K; Caruso, A; Castelli, F; Comelli, A; Focà, E; Gasparotti, R; Gazzina, S; Leonardi, M; Masciocchi, S; Nocivelli, S; Odolini, S; Padovani, A; Pasolini, MP; Pezzini, A; Pilotto, A; Volonghi, I; Zetterberg, H | 1 |
| Jilma, B; Karolyi, M; Schoergenhofer, C; Stimpfl, T; Zoufaly, A | 1 |
| Estella, Á; Garnacho-Montero, J | 1 |
| Marto, N; Monteiro, EC | 1 |
| Aggarwal, G; Aggarwal, S; Bangalore, S; Henry, BM | 1 |
| Dan, BT; Gao, YH; Huang, L; Liu, XY; Yan, D; Zhang, GJ; Zhu, YN | 1 |
| Aliberti, S; Blasi, F; Bollati, V; Di Cosola, R; Ratti, A; Rota, F; Rota, I; Ruscica, M; Vicenzi, M | 1 |
| Berger, SP; Kosterink, JGW; Nannan Panday, PV; Toren-Wielema, ML; Touw, DJ; Zijp, TR | 1 |
| Cattaneo, D; Clementi, E; Corbellino, M; Galli, M; Gervasoni, C; Riva, A | 1 |
| Abuzeid, H; AlAkhras, A; AlMessabi, AH; Khoo, S; Nsutebu, EF | 1 |
| Bellouard, R; Boutoille, D; Canet, E; Gaborit, BJ; Gregoire, M; Imbert, BM; Le Turnier, P; Lecomte, R; Raffi, F; Veyrac, G | 1 |
| Atzrodt, CL; Clements, TP; Maknojia, I; McCarthy, RDP; Oldfield, TM; Po, J; Stepp, HE; Ta, KTL | 1 |
| Bertazzoni, G; Lund, VJ; Mangiatordi, F; Morello, R; Pianta, L; Trimarchi, M; Vinciguerra, A | 1 |
| Alffenaar, JW; Andréjak, C; Bachez, P; Bart, PA; Belilovski, E; Blanc, FX; Borisov, S; Cardoso-Landivar, J; Centis, R; Codecasa, LR; D'Ambrosio, L; Dominguez-Castellano, A; Dourmane, S; Fréchet Jachym, M; Froissart, A; García-García, JM; Giacomet, V; Goletti, D; Grard, S; Gualano, G; Izadifar, A; Le Du, D; Luiza De Souza-Galvão, M; Marín Royo, M; Mazza-Stalder, J; Migliori, GB; Motta, I; Ong, CWM; Palmieri, F; Rivière, F; Rodrigo, T; Sánchez-Montalvá, A; Saporiti, M; Scarpellini, P; Schlemmer, F; Silva, DR; Sotgiu, G; Spanevello, A; Sumarokova, E; Tabernero, E; Tadolini, M; Tambyah, PA; Tiberi, S; Torre, A; Visca, D; Zabaleta Murguiondo, M | 1 |
| Habibzadeh, P; Lankarani, KB; Moghadami, M | 1 |
| Owa, AB; Owa, OT | 1 |
| Doggrell, SA | 1 |
| Darazam, IA; Golmohammadi, M; Irvani, SSN; Pourhoseingholi, MA; Shokouhi, S | 1 |
| Chen, K; Couban, RJ; Du, X; Gong, X; Guyatt, G; He, N; Ibrahim, QI; Li, X; Li, Y; Liu, F; Liu, J; Liu, W; Shen, N; Tang, Q; Wu, Z; Xu, X; Ye, Z; Ying, Y; Zhai, S; Zhang, Q; Zhang, Y; Zhou, P | 1 |
| Chen, L; Ding, JG; Hong, L; Li, J; Sun, GQ; Sun, QF; Ye, EL; Yu, XQ; Zhang, XX | 1 |
| Campos, L; Gouveia, CC | 1 |
| Dalili, N; Fatemizadeh, S; Firouzan, A; Kashefizadeh, A; Nafar, M; Poorrezagholi, F; Samadian, F; Samavat, S; Ziaie, S | 1 |
| Gidea, CG; Mehta, SA; Moazami, N; Reyentovich, A; Stachel, MW | 1 |
| Amore, A; Bimonte, S; Cascella, M; Celentano, E; Crispo, A; Cuomo, A | 1 |
| Danion, F; Fourtage, M; Greigert, V; Hansmann, Y; Kaeuffer, C; Lefebvre, N; Muller, J; Nai, T; Ruch, Y | 1 |
| Bai, K; Chen, H; Fu, Y; Hu, J; Li, C; Liu, C; Liu, W; Qin, Y; Xu, F; Zhang, Q | 1 |
| Chen, D; Dong, L; Pan, X; Peng, C; Yang, L | 1 |
| De La Casa-Fages, B; Grandas, F; Mas Serrano, M; Mato Jimeno, V; Pérez Tamayo, I; Pérez-Sánchez, JR; Portela Sánchez, S | 1 |
| Di Perri, G | 1 |
| Alonso-Herreros, JM; Berisa-Prado, S; Cañete-Ramírez, C; Dávila-Pousa, C; Flox-Benítez, MDP; Ladrón de Guevara-García, M; López-Cabezas, C; Martín de Rosales-Cabrera, AM; Ramos-Martínez, B | 1 |
| Martin, GS; Tekwani, S; Yang, P | 1 |
| Rockstroh, JK; Waters, L | 1 |
| Bae, IG; Cho, OH; Chong, YP; Hong, KW; Hong, SI; Kim, HC; Kim, S; Lee, S; Ryu, BH | 1 |
| Abedini, A; Baghaei, P; Dastan, F; Hashemian, SM; Jamaati, H; Marjani, M; Moniri, A; Nadji, SA; Saffaei, A; Tabarsi, P; Varahram, M; Yousefian, S | 1 |
| Cai, C; Deng, Y; Hu, ZY; Huang, K; Huang, Y; Wang, X; Wang, Y; Xie, J; Xie, Y; Xu, D; Zang, J; Zhan, T; Zheng, F | 1 |
| Back, D; Battegay, M; Hirsch, HH; Khoo, S; Marzolini, C; Stader, F; Stoeckle, M | 1 |
| Kumar, Y; Patel, CN; Singh, H | 1 |
| Adnan, M; Chaudhari, G; Jolly, T; Mansuri, Z; Shah, B | 1 |
| Magro, G | 1 |
| Gafarova, AR; Gainullina, EN; Timerbulatov, SV; Timerbulatov, VM; Timerbulstov, MV | 1 |
| Cemillán-Fernández, CA; Domingo-García, J; Fouz-Ruiz, D; Gómez-Enjuto, S; Hernando-Requejo, V; Lapeña-Motilva, J; Ogando-Durán, G; Rodríguez-García, E | 1 |
| Davies, M; Denyer, J; Dhanda, S; Evans, A; Lane, S; Osborne, V; Roy, D; Shakir, S | 1 |
| Fueyo-Rodriguez, O; Moreno-Sanchez, F; Palomar-Lever, A; Valente-Acosta, B | 1 |
| Jin, H; Yin, G; Zhang, C | 1 |
| Adachi, E; Hoshina, T; Ikeuchi, K; Saito, M; Yotsuyanagi, H | 1 |
| Cai, ZB; Huang, JS; Liu, F; Niu, HY; Sui, DM; Wang, F; Xu, AF; Xue, LZ; Yu, WY; Zhang, Y | 1 |
| Li, C; Ren, L; Wang, L | 1 |
| Bernal-Bello, D; Canalejo-Castrillero, E; Duarte-Millán, MÁ; Farfán-Sedano, AI; Frutos-Pérez, B; García de Viedma-García, V; Llarena-Barroso, C; Morales-Ortega, A; Ruiz-Giardín, JM; Ruiz-Ruiz, J; San Martín-López, JV | 1 |
| Aguado, P; Balsa, A; Bernad-Pineda, M; Bogas, P; Bonilla, G; Castilla-Plaza, A; De Miguel, E; Franco-Gómez, K; García-Lorenzo, E; Miranda-Carus, ME; Monjo, I; Novella Navarro, M; Nuño, L; Peiteado, D; Rodríguez-Araya, T; Tornero, C; Villalba, A | 1 |
| Fenioux, C; Funck-Brentano, C; Gligorov, J; Gougis, P; Solas, C; Spano, JP; Veyri, M | 1 |
| Baombe, J; Dolan, D; Ingham, J | 1 |
| Chan, JCN; Chen, J; Chen, X; Deng, Y; He, X; Hong, W; Qiu, S; Wang, J; Zeng, J; Zhang, Y; Zheng, H; Zhu, B | 1 |
| Baek, JH; Im, JH; Kwon, HY; Lee, JS; Nahm, CH | 1 |
| Chen, G; Chen, H; Chen, Y; Hong, Z; Huang, M; Liu, S; Liu, X; Shang, Y; Xia, J; Zhou, Y; Zhu, H | 1 |
| Baettig, V; Bassetti, S; Battegay, M; Egli, A; Franzeck, F; Gebhard, CE; Geenen, J; Hirsch, HH; Hollinger, A; Khanna, N; Marzolini, C; Mueller, D; Osthoff, M; Sendi, P; Stader, F; Stoeckle, M; Tschudin-Sutter, S; Weisser, M | 1 |
| Cauda, R; Cingolani, A; Cipriani, MC; Fantoni, M; Gremese, E; Larosa, L; Liperoti, R; Montemurro, G; Murri, R; Pasciuto, G; Pirronti, T; Tummolo, AM | 1 |
| Cleland, E; Giovane, RA; Henderson, CE; Rezai, S | 1 |
| Arzoine, J; Beurton, A; Boutolleau, D; Bureau, C; Burrel, S; Clarac, U; Clovet, O; De Sarcus, M; Decavele, M; Delemazure, J; Deleris, R; Demoule, A; Dres, M; Duceau, B; Faure, M; Grisot, PH; Haudebourg, L; Le Marec, J; Lecronier, M; Mayaux, J; Mora, P; Morawiec, E; Nemlaghi, S; Pari, MH; Raux, M; Virolle, S | 1 |
| Abbasian, L; Davoudi-Monfared, E; Hajiabdolbaghi, M; Kazemzadeh, H; Khalili, H; Rahmani, H; Salehi, M; Yekaninejad, MS | 1 |
| Demirkan, K; Fırat, O; Yalçın, N | 1 |
| Bowen, A; Davis, J; Denholm, JT; Morpeth, S; O'Sullivan, M; Paterson, D; Price, D; Rees, M; Roberts, J; Snelling, T; Tong, SYC; Zentner, D | 1 |
| Ahn, MY; Choi, JP; Hong, KH; Kim, S; Lee, JH; Lee, YK; Oh, DH | 1 |
| Cai, J; Lang, G; Ni, Q; Shen, X; Sheng, J; Su, J; Wu, W; Xu, K; Zhao, H; Zhu, B | 1 |
| Bai, ZF; Bi, JF; Chen, Z; Ding, JB; Dong, JH; Guo, YM; He, DC; Jiang, TJ; Jing, J; Li, PY; Niu, M; Qin, EQ; Song, XA; Sun, YQ; Tang, JY; Wang, JB; Wang, RL; Wang, ZX; Wu, D; Xiao, XH; Xu, Z; Yang, G; Yu, SM; Zhan, XY; Zhang, P; Zhang, ZT; Zhao, P; Zhao, PF; Zhao, X; Zhou, YF | 1 |
| Izcovich, A; Rada, G; Ragusa, M; Verdugo-Paiva, F | 1 |
| Brun, P; Dubois, J; Dulière, V; Julien, T; Lina, B; Padey, B; Pizzorno, A; Rosa-Calatrava, M; Terrier, O; Traversier, A | 1 |
| Li, Z; Liu, Y; Wang, D | 1 |
| Bouadma, L; de Montmollin, E; Descamps, D; Jaquet, P; Kauv, J; Laouénan, C; Le Hingrat, Q; Lê, MP; Patrier, J; Peytavin, G; Sonneville, R; Timsit, JF; Veyrier, M; Visseaux, B; Wicky, PH | 1 |
| Cui, M; Guo, Y; Hong, P; Hou, Z; Liu, F; Lu, Y; Qian, X; Qiu, F; Song, P; Tong, G; Wan, D; Wang, N; Wang, S; Wang, X; Xu, Y; Yu, H; Zhan, Y; Zheng, Z; Zhu, L; Zou, X | 1 |
| Acosta, S; Dunk, C; Kala, S; Serghides, L | 1 |
| Brandariz-Nuñez, D; Correas-Sanahuja, M; García, B; Gil, R; Guarc, E; Picón, R | 1 |
| Álvarez, ED; Castro, CÁ; Morales, CM; Robles, AL; Sandoval, TP; Santos, CS | 1 |
| Cao, J; Fan, L; He, F; Hu, K; Lei, M; Luo, Q; Qin, S; Shao, X; Yang, L; Yu, N | 1 |
| Argov, Z; Gotkine, M; Haham, N; Orenbuch-Harroch, E; Rein, N; Romain, M; Vaknin-Dembinsky, A | 1 |
| Agarwal, A; Agoritsas, T; Azab, M; Bartoszko, JJ; Bravo, G; Brignardello-Petersen, R; Chu, DK; Couban, R; Devji, T; Escamilla, Z; Foroutan, F; Gao, Y; Ge, L; Ghadimi, M; Guyatt, GH; Han, MA; Heels-Ansdell, D; Honarmand, K; Hou, L; Ibrahim, Q; Izcovich, A; Khamis, A; Kum, E; Lam, B; Lamontagne, F; Loeb, M; Mansilla, C; Marcucci, M; Martinez, JPD; McLeod, SL; Miroshnychenko, A; Motaghi, S; Murthy, S; Mustafa, RA; Pardo-Hernandez, H; Qasim, A; Rada, G; Rizwan, Y; Saadat, P; Siemieniuk, RA; Switzer, C; Thabane, L; Tomlinson, G; Vandvik, PO; Vernooij, RW; Viteri-García, A; Wang, Y; Yao, L; Zeraatkar, D; Zhao, Y | 1 |
| Airó, P; Andreoli, L; Bertasi, V; Bianchi, M; Bottone, D; Brucato, A; Civelli, P; Colombo, E; Cotelli, MS; Damiolini, E; Franceschini, F; Furloni, R; Galbassini, G; Gatta, D; Ghirardelli, ML; Magri, R; Malamani, P; Mendeni, M; Miclini, M; Molinari, S; Morotti, A; Piantoni, S; Richini, D; Salada, L; Scarsi, M; Tincani, A; Turla, M; Vender, A | 1 |
| Chen, M; Chen, Z; Gao, G; Ma, X; Qian, F; Wang, A; Wang, S; Wang, X; Yu, F; Zhang, F; Zhang, J; Zhao, T | 1 |
| Cseprekál, O; Doros, A; Fazakas, J; Földes, K; Gerlei, Z; Haboub-Sandil, A; Kóbori, L; Marton, A; Patonai, A; Remport, Á; Smudla, A; Török, S; Varga, M; Wagner, L | 1 |
| Barbonetti, A; Berardicurti, A; Berardicurti, O; D'Andrea, S; Felzani, G; Francavilla, F; Francavilla, S; Giacomelli, R | 1 |
| Alves, CR; Bozza, FA; Bozza, PT; Cardoso Soares, V; Carels, N; da Silva Gomes Dias, S; de Freitas, CS; Ferreira, AC; Fintelman-Rodrigues, N; Matos, AR; Mattos, M; Miranda, MD; Ribeiro Lima, C; Sacramento, CQ; Siqueira, MM; Souza da Silva, F; Souza, TML; Temerozo, JR | 1 |
| Gan, W; Gu, J; Li, H; Li, Y; Lu, C; Luo, P; Miao, H; Tian, M; Wang, J; Wang, S; Wu, M; Yao, Y; Yuan, B; Zhao, D; Zhao, X | 1 |
| Cheng, X; Guan, X; Jin, L; Liang, L; Liao, X; Liu, Y; Shi, Y; Song, L; Su, R; Wang, J; Xin, S; Xing, L; Xu, X; Yang, F; Yu, R; Yu, Y; Zhang, D; Zhou, W; Zhu, B | 1 |
| Balerdi-Sarasola, L; Gainzarain-Arana, JC; Ganchegui-Aguirre, M; Molina-Iturritza, E; Ortiz-de-Zárate-Ibarra, Z; Portu-Zapirain, J; San-José-Muñiz, I | 1 |
| Barba-Gyengo, N; Cabrero-Rodríguez, C; Fernández-García, MÁ; Gámez-Baeza, P; Gámiz-Molina, AB; García-Martín, M; Guirado-Ruiz, PA; Jiménez-Mejías, E; Láinez-Ramos-Bossini, AJ; Mancera-Romero, J; Martín-delosReyes, LM; Martín-Romero, DT; Martínez-Diz, S; Martínez-Ruiz, V; R-delAmo, JL; Rivera-Izquierdo, M; Rodríguez-Camacho, M; Sánchez-Pérez, MR; Tahery-Mahmoud, A; Valero-Ubierna, MDC | 1 |
| Al-Yamani, MJ; Asdaq, SMB; Jomah, S | 1 |
| Del Pozo-Carlavilla, M; Díaz-Merchán, R; Domínguez-Pinilla, N; Fernandez-Escobar, V; Pérez-Heras, I; Valerio-Alonso, ME | 1 |
| Ijaz, M; Khan, M; Kharaba, ZJ; Murtaza, G; Shamim, S | 1 |
| Bourlon, C; Bourlon, MT; Carretero-Gonzalez, A; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberon, M; Remolina-Bonilla, YA | 1 |
| Alberio, L; Stalder, G | 1 |
| Álvaro-Gracia, J; Castrejón, I; González, T; Martínez-Barrio, J; Molina Collada, J; Montero, F; Rivera, J; Serrano-Benavente, B | 1 |
| Alvaro-Gracia, JM; Blanco, R; Carmona, L; Castrejón, I; Fernández Fernández, D; Fernandez-Nebro, A; Galindo, M; Gonzalez-Gay, MA; Lledó, A; Manrique-Arija, S; Martinez-Lopez, D; Mena Vázquez, N; Mera-Varela, A; Pablos, JL; Retuerto, M | 1 |
| Abou-Arab, O; Beyls, C; Hermida, A; Mahjoub, Y; Martin, N | 1 |
| Hadda, V; Misra, S; Nath, M; Vibha, D | 1 |
| Brown, F; Cotton, MF; Decloedt, EH; Dodds, MG; Dron, L; Mills, EJ; Niranjan, V; Park, JJH; Rayner, CR; Reis, G; Smith, PF; Wesche, D | 1 |
| Balzarini, L; Ferrozzi, F; Mancini, C; Marvisi, M; Ramponi, S; Uccelli, M | 1 |
| Alharthy, A; Alshaya, R; Brindley, PG; Faqihi, F; Karakitsos, D; Kutsogiannis, DJ; Papanikolaou, J | 1 |
| Ahmadinejad, Z; Ghiasvand, F; Golestan, FS; Hajiabdolbaghi, M; Jafari, F; Jafari, S; Jamalimoghadamsiahkali, S; Khalili, H; Kouchak, HE; Manafi, N; Pirhayati, M; Sadr, S; Salehi, M; Seifi, A; Sekhavati, E; SeyedAlinaghi, S; Tabarestani, M; Zendehdel, A | 1 |
| Ding, C; García, JA; García-Abellán, J; García-Pachón, E; Guillén, L; Gutiérrez, F; Masiá, M; Mora, A; Padilla, S; Telenti, G | 1 |
| Duburcq, T; Lassailly, G; Levy, C; Mathurin, P; Parmentier, E; Poissy, J | 1 |
| Filipova, E; Pavlova, V; Uzunova, K; Vekov, T | 1 |
| Chae, H; Jeong, HJ; Jeong, K; Kim, S; Lee, G; Min, S; Namgoong, SK | 1 |
| Catino, A; Galetta, D; Longo, V; Montrone, M; Palmieri, VO | 1 |
| Birlutiu, V; Iancu, GM; Solomon, A | 1 |
| de Victoria Fernández, B; González Sánchez, IC; Redondo-Sendino, Á | 1 |
| Akahoshi, T; Iwasaka, S; Maki, J; Nagasaki, Y; Nakashima, K; Shimono, N; Shono, Y; Taguchi, T; Tokuda, K; Yamamoto, Y | 1 |
| Einav, S; Servillo, G; Vargas, M | 1 |
| Guo, F; Li, S; Liu, C; Shang, D; Taleb, SJ; Tong, M | 1 |
| Chen, H; Deng, C; Du, Q; Guo, Y; Huang, X; Li, T; Lu, S; Yue, R | 1 |
| Alberici, I; Cattelan, AM; Di Meco, E; Farinati, F; Fassan, M; Guarnaccia, A; Trevenzoli, M | 1 |
| Antonijević Miljaković, E; Antonijević, B; Baralić, K; Buha Djordjevic, A; Ćurčić, M; Jorgovanović, D; Živančević, K; Đukić-Ćosić, D | 1 |
| Jones, CW; Platts-Mills, TF; Woodford, AL | 1 |
| Luo, S; Tian, M; Wang, L; Xia, W; Zeng, Y; Zha, Y; Zhang, K; Zhang, X | 1 |
| Ader, F | 1 |
| Betancourt, JR; Domínguez, RE; González, D; López, LDR; Mezquia, N; Pereda, R; Pérez, A; Rivero, HB; Rivero, JC; Venegas, R | 1 |
| Alshaeri, HK; Natto, ZS | 1 |
| Emanuela, C; Francesco, L; Giorgia, G; Pasquale, N; Roberto, P; Sara, D | 1 |
| Li, D; Liu, T; Liu, Y; Luo, F; Wang, B; Wang, H | 1 |
| Bodini, FC; Cavanna, L; Colombi, D; Michieletti, E; Milanese, G; Morelli, N; Silva, M | 1 |
| Abdelzaher, M; Al Bshabshe, A; Al Faraj, S; Al Harbi, S; Al Jeraisy, M; Al Johani, S; Al Mekhlafi, GA; Al Saedi, A; Al-Dawood, A; Al-Hameed, F; Alharbi, NK; AlMutairi, BM; Alothman, A; Arabi, YM; Asiri, AY; Assiri, AM; Azzam, MHA; Bajhmom, W; Balkhy, HH; Bin Eshaq, AM; Deeb, AM; Elzein, FE; Fowler, RA; Ghazal, S; Hayden, FG; Hussein, MA; Jokhdar, HAA; Jose, J; Mandourah, Y; Memish, ZA; Sherbeeni, NM | 1 |
| Hirano, Y; Komatsu, TS; Koyama, YM; Morimoto, G; Ohno, Y; Okimoto, N; Taiji, M | 1 |
| Carboni Bisso, I; Catanzariti, A; Las Heras, M; Vecchio, G; Zapico, V | 1 |
| Bahurupi, YA; Bandyopadhyay, A; Chikara, G; Moirangthem, B; Panda, PK; Saha, S; Singh, BC | 1 |
| Alavi Darazam, I; Hajesmaeili, MR; Hatami, F; Irvani, SSN; Moradi, O; Pourhoseingholi, MA; Rabiei, MM; Shabani, M; Shokouhi, S | 1 |
| Bazram, A; Fathalipour, M; Hassaniazad, M; Hassanipour, S | 1 |
| Bertozzi, SM; Cohen, J; Forsythe, S; Kinghorn, A; Neumann, P | 1 |
| Dunning, J; Ison, M; Lee, N | 1 |
| Hung, IF; Yuen, KY | 1 |
| Cao, Z; Huang, K; Jiang, D; Wang, W; Xie, Y; Zheng, F; Zhou, J; Zhou, Z | 1 |
| Agoritsas, T; Andrey, DO; Back, M; Battegay, M; Calmy, A; Chappuis, F; Decosterd, L; Fuchs, S; Guessous, I; Jacquerioz, F; Kaiser, L; Labhardt, ND; Lebowitz, D; Marinosci, A; Meyer, B; Nicoletti, GJ; Perneger, T; Ragozzino, S; Salamun, J; Schaubhut, C; Smit, M; Spechbach, H; Stoeckle, M | 1 |
| Arbustini, E; Bergomi, P; Bozzini, S; Cavagna, L; Colombo, R; Corsico, AG; Cova, E; D'Amato, M; Di Toro, A; Fossali, T; Frangipane, V; Lettieri, S; Lilleri, D; Meloni, F; Mojoli, F; Morosini, M; Ottolina, D; Pandolfi, L; Percivalle, E; Saracino, L; Tomaselli, S; Urtis, M | 1 |
| Ahmadinejad, Z; Assari, R; Ayoobi Yazdi, N; Javanshayani, P; Khalili Afousi, H; Mazloomi, SH; Ziaee, V | 1 |
| Mishra, SK; Tripathi, T | 1 |
| Chen, J; Hu, BJ; Lin, HF; Luo, Y; Shi, ZL; Zhao, K | 1 |
| De Vito, A; Madeddu, G | 1 |
| Ceccarelli, M; Nunnari, G; Pavone, P; Venanzi Rullo, E | 1 |
| Li, X; Liu, J; Luo, R; Wu, D; Wu, L; Xu, P; Zheng, Y | 1 |
| Abdelaziz, A; Abdelgaleel, M; Alaa El-Din, M; Madian, H; Salem, H; Samir, E; Zein, D | 1 |
| Al Bshabshe, A; Al Harbi, S; Al Jeraisy, M; Al-Dawood, A; Al-Hameed, F; AlJohani, S; Almekhlafi, GA; Almotairi, A; Alothman, A; AlSaedi, A; Arabi, YM; Assiri, AM; Balkhy, HH; Deeb, AM; Elzein, FE; Fowler, RA; Hayden, FG; Hussein, MA; Jose, J; Kharaba, A; Kojan, S; Maghrabi, KA; Mandourah, Y; Memon, J; Qushmaq, I; Shalhoub, S; Sherbeeni, NM; Taha, Y | 1 |
| Eom, JS; Joo, YS; Jung, Y; Ko, JH; Lee, JS; Park, SY; Peck, KR; Shi, H; Son, JS; Woo, HJ | 1 |
| Al-Tawfiq, JA; Memish, ZA; Mohammed, K; Momattin, H; Zumla, A | 1 |
| Haagmans, BL; Koopmans, MP; Koulouris, NG; Koutsoukou, A; Osterhaus, AD; Pontikis, K; Raj, VS; Spanakis, N; Tsakris, A; Tsiodras, S | 1 |
| Bao, L; Cai, JP; Chan, JF; Chen, H; Chu, H; Deng, W; Gao, H; Jia, L; Li, F; Qin, C; Xiao, C; Yao, Y; Yeung, ML; Yu, P; Yuen, KY; Zhou, J | 1 |
| Jang, HC; Jung, SI; Kee, SJ; Kim, UJ; Won, EJ | 1 |
| Fisher, D; Mo, Y | 1 |
48 review(s) available for lopinavir and Infections, Coronavirus
| Article | Year |
|---|---|
Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials.
Topics: Colchicine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Doxycycline; Humans; Imatinib Mesylate; Immunization, Passive; Immunoglobulins, Intravenous; Interferon beta-1b; Ivermectin; Lopinavir; Methylprednisolone; Network Meta-Analysis; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Ritonavir | 2022 |
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Disease Models, Animal; Humans; Lopinavir; Mice; Middle East Respiratory Syndrome Coronavirus; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Treatment Outcome | 2020 |
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Immunization, Passive; Interferon-beta; Lopinavir; Mice, Transgenic; Middle East Respiratory Syndrome Coronavirus; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus; Spike Glycoprotein, Coronavirus | 2020 |
[Pharmacotherapeutics for the new coronavirus pneumonia].
Topics: Adenosine; Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antiviral Agents; China; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Humans; Lopinavir; Pneumonia, Viral; Retrospective Studies; Ribonucleotides; Ritonavir | 2020 |
Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019.
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; China; Chloroquine; Coronavirus Infections; COVID-19; Female; Humans; Indoles; Infant; Infant, Newborn; Interferon-alpha; Lopinavir; Male; Pandemics; Pharmaceutical Services; Pneumonia, Viral; Practice Guidelines as Topic; Prognosis; Ribavirin; Risk Assessment; Severe Acute Respiratory Syndrome; Treatment Outcome | 2020 |
Potential therapeutic agents against COVID-19: What we know so far.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Hydroxychloroquine; Interferon-alpha; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunomodulation; Interferon-alpha; Lopinavir; Nelfinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ribavirin; Ritonavir; SARS-CoV-2; Sulfonamides; Thiazoles | 2020 |
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunoglobulins; Immunologic Factors; Indoles; Lopinavir; Oseltamivir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Withholding Treatment | 2020 |
Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Thiazoles | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Treatment options for COVID-19: The reality and challenges.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Teicoplanin | 2020 |
Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Continuous Positive Airway Pressure; Coronavirus Infections; COVID-19; Developing Countries; Disease Management; Humans; Hydroxychloroquine; Lopinavir; Lung; Oxygen; Pandemics; Pneumonia, Viral; Respiration, Artificial; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.
Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Antimalarials; Antiviral Agents; Basal Metabolism; Betacoronavirus; Cardiovascular Physiological Phenomena; Chloroquine; Congenital Abnormalities; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disease Susceptibility; Drug Combinations; Drug Delivery Systems; Female; Functional Residual Capacity; Glycyrrhizic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Interferon Type I; Lopinavir; Metformin; Nanoparticles; Oxygen Consumption; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pregnancy; Pregnancy Complications, Infectious; Progesterone; Prognosis; Respiratory Physiological Phenomena; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Stillbirth; Ventilation-Perfusion Ratio | 2020 |
Treatment of SARS-CoV-2: How far have we reached?
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferon-alpha; Interferon-beta; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
COVID-19 in Children: Clinical Approach and Management.
Topics: Acute Lung Injury; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Disease Outbreaks; Humans; Hydroxychloroquine; Infant; Lopinavir; Palliative Care; Pandemics; Pneumonia, Viral; Protease Inhibitors; Respiratory Distress Syndrome; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Bone Marrow Transplantation; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Testing; Drug Combinations; Education, Distance; Hematopoietic Stem Cell Transplantation; Humans; Hydroxychloroquine; Immunization, Passive; Infection Control; Information Dissemination; Lopinavir; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Real-Time Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Tissue Donors | 2020 |
Medical treatment options for COVID-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Recombinant Proteins; RNA, Viral; SARS-CoV-2 | 2020 |
Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Investigational; Global Health; Humans; Hydroxychloroquine; Lopinavir; Off-Label Use; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Alanine; Anti-Infective Agents; Azithromycin; Betacoronavirus; Cardiovascular Diseases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Enzyme Inhibitors; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; COVID-19 Vaccines; Drug Combinations; Humans; Hydroxychloroquine; Interferon beta-1a; Lopinavir; Middle East Respiratory Syndrome Coronavirus; Pandemics; Respiration, Artificial; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Severity of Illness Index | 2020 |
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Evidence-Based Medicine; Humans; Hydroxychloroquine; Indoles; Influenza, Human; Lopinavir; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Coronavirus Disease 2019: Clinical Review.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Azithromycin; Betacoronavirus; Blood Coagulation Disorders; China; Chiroptera; Chloroquine; Coronavirus Infections; COVID-19; Glucocorticoids; Humans; Hydroxychloroquine; Infectious Disease Incubation Period; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Prognosis; Pyrazines; Radiography, Thoracic; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Symptom Assessment | 2020 |
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Indoles; Lopinavir; Multicenter Studies as Topic; Neuraminidase; Pandemics; Pneumonia, Viral; Primates; Ribavirin; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Indoles; Interferons; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis | 2020 |
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Anticoagulants; Antiviral Agents; Azetidines; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Disseminated Intravascular Coagulation; Drug Combinations; Heparin; Humans; Hydroxychloroquine; Inflammation; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ritonavir; SARS-CoV-2; Sulfonamides | 2020 |
[Drug treatment of coronavirus disease COVID-19: evidence exists?]
Topics: Adenosine Monophosphate; Alanine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tissue Plasminogen Activator | 2020 |
Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Indoles; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis; Teicoplanin | 2020 |
BET 1: Lopinavir-ritonavir and COVID-19.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; HIV Protease Inhibitors; Humans; Length of Stay; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Time Factors; Treatment Outcome; Virus Shedding | 2020 |
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Administration Schedule; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis; Treatment Outcome | 2020 |
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Progression; Drug Combinations; Drug Repositioning; Esters; Gabexate; Gene Expression Regulation; Guanidines; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Indoles; Lopinavir; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2020 |
Lopinavir-ritonavir for COVID-19: A living systematic review.
Topics: Adult; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome | 2020 |
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme Inhibitors; Antimalarials; Antiviral Agents; Betacoronavirus; Biomedical Research; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Combinations; Drug Development; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Combinations; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lopinavir; Lung; Lupus Erythematosus, Systemic; Moxifloxacin; Mycophenolic Acid; Pandemics; Pneumonia, Viral; Prednisone; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Viral; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Drug treatments for covid-19: living systematic review and network meta-analysis
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Centers for Disease Control and Prevention, U.S.; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Databases, Factual; Drug Combinations; Evidence-Based Medicine; Glucocorticoids; Humans; Hydroxychloroquine; Lopinavir; Network Meta-Analysis; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Respiration, Artificial; Ritonavir; SARS-CoV-2; Severity of Illness Index; Standard of Care; Treatment Outcome; United States | 2020 |
Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Asymptomatic Diseases; Betacoronavirus; Biomarkers; Child; Clinical Laboratory Techniques; Coronavirus Infections; Cough; COVID-19; COVID-19 Testing; Drug Combinations; Early Diagnosis; Fever; Humans; Hydroxychloroquine; Interferon-alpha; Lopinavir; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Ribavirin; Ritonavir; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed | 2020 |
Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Indoles; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Potential strategies for combating COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Vaccines; Cytokine Release Syndrome; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunologic Factors; Indoles; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Severity of Illness Index; Viral Vaccines | 2020 |
Efficacy of various treatment modalities for nCOV-2019: A systematic review and meta-analysis.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Europe; Female; Humans; Lopinavir; Male; Pandemics; Pneumonia, Viral; Prognosis; Ritonavir; Survival Analysis; Treatment Outcome | 2020 |
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Topics: Antiviral Agents; Betacoronavirus; Clinical Studies as Topic; Coronavirus Infections; COVID-19; Databases, Factual; Humans; Lopinavir; Middle East Respiratory Syndrome Coronavirus; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
Traditional Chinese Medicine as Potential Therapy for COVID-19.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Combinations; Drugs, Chinese Herbal; Humans; Indoles; Janus Kinase Inhibitors; Lopinavir; Medicine, Chinese Traditional; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
A contemporary look at COVID-19 medications: available and potentially effective drugs.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Imatinib Mesylate; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Current treatment of COVID-19 in renal patients: hope or hype?
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal; Cobicistat; Coronavirus Infections; COVID-19; Darunavir; Drug Combinations; Humans; Kidney; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ritonavir | 2020 |
One year update on the COVID-19 pandemic: Where are we now?
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Drug Combinations; Drug Repositioning; Glucocorticoids; Humans; Hydroxychloroquine; Indoles; Ivermectin; Lopinavir; Mutation; Pandemics; Phytotherapy; Plant Extracts; Pyrazines; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tinospora; Viral Zoonoses | 2021 |
Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
Topics: Adult; Aged; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Lopinavir; Male; Middle Aged; Ritonavir; Severe Acute Respiratory Syndrome; Young Adult | 2021 |
Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.
Topics: Antiviral Agents; Coronavirus Infections; Humans; Interferon-alpha; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Treatment Outcome | 2013 |
A review of treatment modalities for Middle East Respiratory Syndrome.
Topics: Antibodies, Viral; Antiviral Agents; Coronavirus Infections; Global Health; Humans; Immunologic Factors; Interferon-beta; Lopinavir; Ribavirin | 2016 |
22 trial(s) available for lopinavir and Infections, Coronavirus
| Article | Year |
|---|---|
Heterogeneity of treatment effect of interferon-β1b and lopinavir-ritonavir in patients with Middle East respiratory syndrome by cytokine levels.
Topics: Animals; Antiviral Agents; Coronavirus Infections; Cytokines; Humans; Interferons; Lopinavir; Ritonavir | 2022 |
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial.
Topics: Antiviral Agents; Coronavirus Infections; Data Interpretation, Statistical; Double-Blind Method; Drug Combinations; Host-Pathogen Interactions; Humans; Interferon beta-1b; Lopinavir; Middle East Respiratory Syndrome Coronavirus; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ritonavir; Saudi Arabia; Time Factors; Treatment Outcome | 2020 |
Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protoc
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Interferon-alpha; Lopinavir; Middle Aged; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Female; Hospital Mortality; Humans; Intention to Treat Analysis; Lopinavir; Male; Middle Aged; Pandemics; Patient Acuity; Pneumonia, Viral; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Time-to-Treatment; Treatment Failure; Viral Load | 2020 |
Treating COVID-19 with Chloroquine.
Topics: Adult; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Lopinavir; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hong Kong; Hospitalization; Humans; Interferon beta-1b; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Drug Therapy, Combination; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Interferon beta-1a; Interferon beta-1b; Iran; Lopinavir; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Severity of Illness Index; Time Factors; Treatment Outcome | 2020 |
Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.
Topics: Betacoronavirus; Colchicine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Drug Combinations; Hospitalization; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Prospective Studies; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2 | 2020 |
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Injections, Subcutaneous; Interferon beta-1a; Lopinavir; Lung; Male; Middle Aged; Pandemics; Pneumonia, Viral; Prospective Studies; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2020 |
Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Prospective Studies; Ritonavir; SARS-CoV-2 | 2020 |
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hydroxychloroquine; Intensive Care Units; Interferon beta-1a; Length of Stay; Lopinavir; Male; Middle Aged; Neoplasms; Pandemics; Patient Safety; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Survival Analysis; Treatment Outcome | 2020 |
The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study prot
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Hospitalization; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Standard of Care | 2020 |
Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.
Topics: Administration, Inhalation; Adult; China; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Integrative Medicine; Interferon-alpha; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Risk Assessment; Severe Acute Respiratory Syndrome; Severity of Illness Index; Survival Rate | 2020 |
Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial.
Topics: Adult; Aged; Anti-Infective Agents; Azithromycin; Betacoronavirus; C-Reactive Protein; Coronavirus Infections; COVID-19; Disease Progression; Drug Combinations; Female; Heart Rate; Humans; Hydroxychloroquine; Intensive Care Units; Lopinavir; Male; Middle Aged; Pandemics; Patient Safety; Pneumonia, Viral; Prognosis; Respiratory Function Tests; Ritonavir; SARS-CoV-2; Survival Analysis; T-Lymphocytes; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Early Warning Score; Extracorporeal Membrane Oxygenation; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Interferon beta-1a; Length of Stay; Lopinavir; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Respiration, Artificial; Ritonavir; SARS-CoV-2; Standard of Care; Treatment Outcome | 2020 |
Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome.
Topics: Administration, Oral; Adult; Aged; Coronavirus Infections; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Injections, Subcutaneous; Interferon beta-1b; Kaplan-Meier Estimate; Lopinavir; Male; Middle Aged; Ritonavir; Statistics, Nonparametric; Time-to-Treatment | 2020 |
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Topics: Administration, Oral; Adult; Antimalarials; Antiviral Agents; Betacoronavirus; Clinical Protocols; Combined Modality Therapy; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Female; Humans; Hydroxychloroquine; India; Informed Consent; Lopinavir; Male; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; Safety; SARS-CoV-2; Time Factors; Treatment Outcome | 2020 |
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l t
Topics: Adult; Antiviral Agents; Betacoronavirus; Case-Control Studies; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Combinations; Humans; Interferon beta-1a; Lopinavir; Mortality; Outcome Assessment, Health Care; Pandemics; Patient Discharge; Pneumonia, Viral; Respiration, Artificial; Ritonavir; SARS-CoV-2 | 2020 |
Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Topics: Adult; Amides; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Interferons; Iran; Lopinavir; Male; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Viral Load | 2020 |
Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Post-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Switzerland | 2020 |
Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial.
Topics: Antiviral Agents; Coronavirus Infections; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Interferon beta-1b; Lopinavir; Male; Middle East Respiratory Syndrome Coronavirus; Multicenter Studies as Topic; Patient Admission; Randomized Controlled Trials as Topic; Ritonavir; Saudi Arabia; Time Factors; Treatment Outcome | 2018 |
176 other study(ies) available for lopinavir and Infections, Coronavirus
| Article | Year |
|---|---|
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells | 2020 |
Evaluation of the polymorphic forms of ritonavir and lopinavir in raw materials and co-milled systems.
Topics: Antiviral Agents; Coronavirus Infections; Drug Combinations; Humans; Lopinavir; Ritonavir | 2022 |
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Carboxylesterase; Coronavirus Infections; Drug Combinations; Drug Development; Female; Humans; Interferon-beta; Lopinavir; Lung Injury; Male; Mice; Mice, Knockout; Middle East Respiratory Syndrome Coronavirus; Ritonavir; Viral Load; Virus Replication | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Discovery; Humans; Lopinavir; Neuraminidase; Nucleosides; Pneumonia, Viral; Ribonucleotides; Ritonavir; SARS-CoV-2 | 2020 |
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.
Topics: Adult; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Indoles; Lopinavir; Male; Middle Aged; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Young Adult | 2020 |
Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR.
Topics: Betacoronavirus; China; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; COVID-19 Vaccines; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Humans; Lopinavir; Male; Middle Aged; Pneumonia; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; Republic of Korea; Ritonavir; SARS-CoV-2; Viral Load | 2020 |
More than 80 clinical trials launch to test coronavirus treatments.
Topics: Adenosine Monophosphate; Alanine; Animals; Anti-HIV Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Dioxanes; Disease Models, Animal; Drug Combinations; Humans; Immunization, Passive; Lopinavir; Medicine, Chinese Traditional; Monosaccharides; Pandemics; Pneumonia, Viral; Registries; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome; Stem Cell Transplantation; Steroids; Time Factors; Treatment Outcome; World Health Organization | 2020 |
Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR.
Topics: Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Humans; Lopinavir; Pandemics; Pneumonia; Pneumonia, Viral; Republic of Korea; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2 | 2020 |
The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR.
Topics: Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Humans; Lopinavir; Pandemics; Pneumonia; Pneumonia, Viral; Republic of Korea; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2 | 2020 |
[Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer].
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Drug Monitoring; Humans; Lopinavir; Neoplasms; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Progression; Drug Combinations; Female; Humans; Lopinavir; Male; Middle Aged; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Polymerase Chain Reaction; Respiratory Tract Infections; Ritonavir; SARS-CoV-2; Singapore; Virus Shedding | 2020 |
Treatment and Outcome of a Patient With Lung Cancer Infected With Severe Acute Respiratory Syndrome Coronavirus-2.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Lopinavir; Lung; Lung Neoplasms; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China.
Topics: Anti-HIV Agents; Betacoronavirus; China; Clinical Laboratory Techniques; Coinfection; Coronavirus Infections; COVID-19; COVID-19 Testing; Diabetes Mellitus, Type 2; Drug Combinations; gamma-Globulins; HIV; HIV Infections; Humans; Lopinavir; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019.
Topics: Adolescent; Adult; Betacoronavirus; China; Clinical Laboratory Techniques; Contact Tracing; Coronavirus Infections; COVID-19; COVID-19 Testing; Female; Humans; Interferon alpha-2; Lopinavir; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Oropharynx; Oxygen; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; RNA, Viral; SARS-CoV-2; Severity of Illness Index; T-Lymphocytes; Tomography, X-Ray Computed | 2020 |
[Potential antiviral therapeutics for 2019 Novel Coronavirus].
Topics: Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inhibitors; Humans; Interferon-beta; Lopinavir; Middle East Respiratory Syndrome Coronavirus; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
Topics: Administration, Oral; Adult; Antiviral Agents; Cohort Studies; Coronavirus Infections; COVID-19; Drug Combinations; Drug Therapy, Combination; Female; Humans; Indoles; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; Tomography, X-Ray Computed | 2020 |
Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disease Progression; Drug Therapy, Combination; Eosinophils; Female; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Asymptomatic Infections; Betacoronavirus; Child; Child, Preschool; China; Coronavirus Infections; COVID-19; Disease Progression; Drug Combinations; Female; Hospitalization; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Time Factors; Treatment Outcome; Young Adult | 2020 |
Covid-19 - The Search for Effective Therapy.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Audio Interview: New Research on Possible Treatments for Covid-19.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19 Drug Treatment; Cross Infection; Diagnosis, Differential; Drug Combinations; Humans; Hydroxychloroquine; Infection Control; Influenza, Human; Lopinavir; Patient Care; Receptors, Virus; Respiration, Artificial; Ritonavir; SARS-CoV-2 | 2020 |
Advance of promising targets and agents against COVID-19 in China.
Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Cobicistat; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Dibenzothiepins; Drug Combinations; Drug Discovery; Drug Therapy, Combination; Emtricitabine; Humans; Hydroxychloroquine; Indoles; Lopinavir; Medicine, Chinese Traditional; Morpholines; Oseltamivir; Oxazines; Pandemics; Pneumonia, Viral; Pyrazines; Pyridines; Pyridones; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tenofovir; Thiepins; Triazines; Viral Nonstructural Proteins | 2020 |
Clinical features and treatment of COVID-19 patients in northeast Chongqing.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Biomarkers; Cardiovascular Diseases; China; Clinical Laboratory Techniques; Coronavirus Infections; Cough; COVID-19; COVID-19 Testing; Diabetes Complications; Diabetes Mellitus; Drug Combinations; Drugs, Chinese Herbal; Fatigue; Female; Fever; Humans; Interferons; Lopinavir; Male; Middle Aged; Neoplasms; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed | 2020 |
Race to find COVID-19 treatments accelerates.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; World Health Organization | 2020 |
The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; China; Coronavirus Infections; COVID-19; Creatine Kinase; Drug Combinations; Humans; Interferon-alpha; L-Lactate Dehydrogenase; Lopinavir; Middle Aged; Pandemics; Pneumonia, Viral; Polymerase Chain Reaction; Retrospective Studies; Ritonavir; RNA, Viral; Young Adult | 2020 |
COVID-19 in kidney transplant recipients.
Topics: Aged; Betacoronavirus; Cobicistat; Colchicine; Coronavirus Infections; COVID-19; Cytokines; Darunavir; Drug Combinations; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lopinavir; Male; Middle Aged; Mycophenolic Acid; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tacrolimus; Transplant Recipients; Treatment Outcome | 2020 |
Combating COVID-19 with Chloroquine.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Endocytosis; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antimetabolites; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Emetine; Epithelial Cells; Homoharringtonine; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; SARS-CoV-2; Vero Cells; Virus Replication | 2020 |
COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies.
Topics: Antiviral Agents; Betacoronavirus; Communicable Disease Control; Coronavirus Infections; COVID-19; Disease Management; Disease Transmission, Infectious; Humans; Hydroxychloroquine; Lopinavir; Mediterranean Region; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.
Topics: Adolescent; Betacoronavirus; Child; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Fever; Humans; Lopinavir; Male; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Lopinavir-ritonavir in severe COVID-19.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
First case of COVID-19 complicated with fulminant myocarditis: a case report and insights.
Topics: Acute Disease; Antiviral Agents; Bacteroides Infections; Betacoronavirus; Biomarkers; Candidiasis; Coronavirus Infections; COVID-19; Drug Combinations; Echocardiography; Fatal Outcome; Humans; Interleukin-6; Lopinavir; Male; Middle Aged; Myocarditis; Pandemics; Piperacillin, Tazobactam Drug Combination; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Stroke Volume; Tomography, X-Ray Computed; Troponin I | 2020 |
Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report.
Topics: Adrenal Cortex Hormones; Adult; Betacoronavirus; China; Coronavirus Infections; COVID-19; Cyclosporine; Disease Outbreaks; Drug Combinations; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Lopinavir; Male; Pandemics; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Transplant Recipients; Treatment Outcome | 2020 |
Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Topics: Adult; Antiviral Agents; Betacoronavirus; C-Reactive Protein; Ciliopathies; Cobicistat; Common Cold; Coronavirus Infections; Cough; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deprescriptions; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Fatigue; Female; Glucocorticoids; Graft Rejection; Humans; Hydroxychloroquine; Immunocompromised Host; Immunosuppressive Agents; Interleukin-10; Interleukin-1beta; Interleukin-6; Interleukin-8; Kidney Diseases, Cystic; Kidney Failure, Chronic; Kidney Transplantation; Leber Congenital Amaurosis; Lopinavir; Methylprednisolone; Optic Atrophies, Hereditary; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Severity of Illness Index; Tacrolimus | 2020 |
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
Topics: Adult; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Female; Humans; Indoles; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Viral Load | 2020 |
Clinical Features of COVID-19-Related Liver Functional Abnormality.
Topics: Adult; Antiviral Agents; Betacoronavirus; Bilirubin; Blood Chemical Analysis; China; Coronavirus Infections; COVID-19; Enzymes; Female; Hospitals; Humans; Liver Diseases; Liver Function Tests; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Prevalence; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2020 |
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Indoles; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Repositioning; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Ritonavir; Sample Size; SARS-CoV-2; United States | 2020 |
COVID-19 in solid organ transplant recipients: A single-center case series from Spain.
Topics: Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Female; Fever; Humans; Hydroxychloroquine; Immunosuppressive Agents; Interferon-beta; Lopinavir; Male; Middle Aged; Organ Transplantation; Pandemics; Pneumonia, Viral; Radiography, Thoracic; Retrospective Studies; Ritonavir; SARS-CoV-2; Spain; Transplant Recipients | 2020 |
COVID-19 tsunami: the first case of a spinal cord injury patient in Italy.
Topics: Anti-Bacterial Agents; Anti-Retroviral Agents; Clinical Laboratory Techniques; Coronavirus Infections; Cough; COVID-19; COVID-19 Testing; Fever; Hospitalization; Humans; Italy; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Quadriplegia; Respiration, Artificial; Ritonavir; Severe acute respiratory syndrome-related coronavirus; Spinal Cord Injuries | 2020 |
Flooded by the torrent: the COVID-19 drug pipeline.
Topics: Adult; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Coronavirus Infections; COVID-19; Drug Combinations; Female; Humans; Hydroxychloroquine; Immunocompromised Host; Lopinavir; Middle Aged; Pandemics; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; Ritonavir; Treatment Outcome | 2020 |
A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: A case report.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Care; Drug Combinations; Extracorporeal Membrane Oxygenation; Humans; Infection Control; Japan; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Respiration, Artificial; Ritonavir; SARS-CoV-2 | 2020 |
Some drugs for COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Neuraminidase; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Darunavir does not prevent SARS-CoV-2 infection in HIV patients.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Darunavir; HIV Infections; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Republic of Korea; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2 | 2020 |
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Dabigatran; Darunavir; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Italy; Lopinavir; Male; Pandemics; Patient Safety; Pneumonia, Viral; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thiazoles | 2020 |
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Female; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2; Taiwan; Virus Shedding | 2020 |
Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics.
Topics: Adult; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drug Interactions; Everolimus; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lopinavir; Male; Netherlands; Pandemics; Pneumonia, Viral; Radiography, Thoracic; Ritonavir; SARS-CoV-2; Transplant Recipients; Treatment Outcome | 2020 |
Two distinct cases with COVID-19 in kidney transplant recipients.
Topics: Adult; Antiviral Agents; Azithromycin; Betacoronavirus; Calcineurin Inhibitors; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Humans; Hydroxychloroquine; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tacrolimus; Transplant Recipients | 2020 |
Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again.
Topics: Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Drug Combinations; Female; Humans; Lopinavir; Middle Aged; Pandemics; Patient Discharge; Pneumonia, Viral; Ribavirin; Ritonavir; RNA, Viral; SARS-CoV-2 | 2020 |
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
Topics: Anti-Infective Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Death, Sudden, Cardiac; Drug Combinations; Drug Monitoring; Drug Repositioning; Electrocardiography; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Pandemics; Pneumonia, Viral; Risk Adjustment; Ritonavir; SARS-CoV-2; Torsades de Pointes | 2020 |
Quadruple therapy for asymptomatic COVID-19 infection patients.
Topics: Asymptomatic Infections; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case report.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Deprescriptions; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Humans; Hypertension; Immunoglobulins, Intravenous; Immunologic Factors; Iran; Lopinavir; Male; Mycophenolic Acid; Oseltamivir; Pandemics; Pemphigoid, Benign Mucous Membrane; Pneumonia, Viral; Prednisolone; Ritonavir; Rituximab; SARS-CoV-2; Tomography, Spiral Computed | 2020 |
A Trial of Lopinavir-Ritonavir in Covid-19.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
A Trial of Lopinavir-Ritonavir in Covid-19.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
A Trial of Lopinavir-Ritonavir in Covid-19.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
A Trial of Lopinavir-Ritonavir in Covid-19.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
A Trial of Lopinavir-Ritonavir in Covid-19.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
A Trial of Lopinavir-Ritonavir in Covid-19. Reply.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression.
Topics: Antineoplastic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Hydroxychloroquine; Immune Tolerance; Infant; Leukemia, Myeloid, Acute; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
A Case of Critically Ill Infant of Coronavirus Disease 2019 With Persistent Reduction of T Lymphocytes.
Topics: Betacoronavirus; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Coronavirus Infections; COVID-19; Critical Illness; Humans; Infant; Lopinavir; Lymphocyte Count; Male; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Virus Shedding | 2020 |
COVID-19 in a patient with pre-existing acute lymphoblastic leukaemia.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Fatal Outcome; Female; Humans; Lopinavir; Meropenem; Middle Aged; Pandemics; Pneumonia, Viral; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Ritonavir; SARS-CoV-2; Teicoplanin | 2020 |
Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokines; Drug Combinations; Female; Humans; Hydroxychloroquine; Intensive Care Units; Lopinavir; Lymphopenia; Male; Middle Aged; Pandemics; Pneumonia, Viral; Republic of Korea; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2020 |
[Chloroquine as a possible treatment for COVID-19].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Lopinavir; Off-Label Use; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Biggest COVID-19 trial tests repurposed drugs first.
Topics: Adaptive Clinical Trials as Topic; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Standard of Care; United Kingdom | 2020 |
Abdominal Visceral Infarction in 3 Patients with COVID-19.
Topics: Abdomen; Aged; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Heparin, Low-Molecular-Weight; Humans; Hydroxychloroquine; Infarction; Italy; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Thrombosis; Tomography, X-Ray Computed; Viscera | 2020 |
Presumed COVID-19 index case on diamond princess cruise ship and evacuees to Hong Kong.
Topics: Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; Hong Kong; Humans; Japan; Lopinavir; Male; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2; Ships; Travel | 2020 |
[The "Historic Study" SOLIDARITY-Research's Answer to the Sars-CoV-2 Pandemic].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Bioethical Issues; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Combinations; Editorial Policies; Humans; Hydroxychloroquine; International Cooperation; Lopinavir; Pandemics; Pneumonia, Viral; Research Design; Ritonavir; SARS-CoV-2; World Health Organization | 2020 |
In Vitro Data of Current Therapies for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Emetine; Homoharringtonine; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; SARS-CoV-2; Teicoplanin; Thiazoles | 2020 |
Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome.
Topics: Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Spain; Tacrolimus; Transplant Recipients | 2020 |
Interferon beta-1b for COVID-19.
Topics: Adjuvants, Immunologic; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Interferon beta-1b; Lopinavir; Multiple Sclerosis; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Betacoronavirus; Ceftriaxone; Cobicistat; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Hydroxychloroquine; Italy; Lopinavir; Male; Methylprednisolone; Middle Aged; Neoplasms; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients-a perspective.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus | 2020 |
First motor seizure as presenting symptom of SARS-CoV-2 infection.
Topics: Betacoronavirus; Brain; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Seizures; Treatment Outcome | 2020 |
Early experience with remdesivir in SARS-CoV-2 pneumonia.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Convalescence; Coronavirus Infections; COVID-19; Critical Illness; Darunavir; Drug Administration Schedule; Drug Combinations; Fatal Outcome; Humans; Hydroxychloroquine; Lopinavir; Multiple Organ Failure; Pandemics; Pneumonia, Viral; Ritonavir; RNA, Viral; SARS-CoV-2; Torsades de Pointes | 2020 |
Steroid-Responsive Encephalitis in Coronavirus Disease 2019.
Topics: Akinetic Mutism; Antiviral Agents; beta 2-Microglobulin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Electroencephalography; Encephalitis; Glucocorticoids; Humans; Hydroxychloroquine; Interleukin-6; Interleukin-8; Lopinavir; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Treatment Outcome; Tumor Necrosis Factor-alpha | 2020 |
Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inhibitors; Female; Humans; Inpatients; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Young Adult | 2020 |
[From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Decision-Making; Clinical Trials as Topic; Coronavirus Infections; Cost-Benefit Analysis; COVID-19; Drug Combinations; Empiricism; Humans; Hydroxychloroquine; Information Dissemination; Lopinavir; Pandemics; Pneumonia, Viral; Reproducibility of Results; Ritonavir; SARS-CoV-2; Viral Load | 2020 |
Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Betacoronavirus; Case-Control Studies; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Hospitalization; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pharynx; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Viral; SARS-CoV-2; Time Factors; Virus Shedding | 2020 |
The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients.
Topics: Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disease Progression; Drug Combinations; Female; Hemodynamics; Humans; Hydroxychloroquine; Hypertension; Italy; Lopinavir; Male; Middle Aged; Oxygen; Pandemics; Pneumonia, Viral; Renin-Angiotensin System; Respiratory Insufficiency; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Important Interactions of Immunosuppressants With Experimental Therapies for Novel Coronavirus Disease (COVID-19): How to Act.
Topics: Adult; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Immunosuppressive Agents; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Therapies, Investigational | 2020 |
Does lopinavir really inhibit SARS-CoV-2?
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Emetine; Homoharringtonine; Humans; Lopinavir; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus | 2020 |
Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?
Topics: Adult; Anti-Infective Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Lopinavir pharmacokinetics in COVID-19 patients.
Topics: Aged; Betacoronavirus; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Female; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19.
Topics: Acetic Acid; Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disinfection; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.
Topics: Adult; Aged; Antitubercular Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Laboratory Techniques; Cohort Studies; Coinfection; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Drug Combinations; Emigrants and Immigrants; Female; Humans; Hydroxychloroquine; Lopinavir; Lung; Male; Middle Aged; Mortality; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Tuberculosis; Tuberculosis, Pulmonary | 2020 |
The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Monitoring; Heart Conduction System; Humans; Hydroxychloroquine; Hypokalemia; Long QT Syndrome; Lopinavir; Magnesium; Pandemics; Pneumonia, Viral; Potassium; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2020 |
Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Resistance, Viral; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Does lopinavir measure up in the treatment of COVID-19?
Topics: Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Ritonavir; Severity of Illness Index; Treatment Outcome; Viral Load | 2020 |
Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.
Topics: Adult; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Feces; Female; Humans; Hypertension; Logistic Models; Lopinavir; Lymphocyte Count; Male; Middle Aged; Odds Ratio; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Viral Load | 2020 |
COVID-19 pneumonia in a dual heart-kidney recipient.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Deception; Drug Combinations; France; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Scholarly Communication | 2020 |
Clinical Analysis of 25 COVID-19 Infections in Children.
Topics: Adolescent; Age Factors; Antiviral Agents; Betacoronavirus; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Child; Child, Preschool; China; Coronavirus Infections; Cough; COVID-19; Female; Fever; Humans; Infant; Lopinavir; Lymphocyte Count; Male; Pandemics; Pneumonia, Viral; Prognosis; Retrospective Studies; Ribavirin; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir.
Topics: Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Serotonin Syndrome; Severe acute respiratory syndrome-related coronavirus | 2020 |
The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection
Topics: Adenosine Monophosphate; Alanine; Anticoagulants; Antiviral Agents; Biomarkers; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Care; Disease Management; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Embolism; Endothelium, Vascular; Heparin, Low-Molecular-Weight; Humans; Hydroxychloroquine; Interferon beta-1b; Lopinavir; Macrophage Activation; Pandemics; Pneumonia, Viral; Pulmonary Fibrosis; Randomized Controlled Trials as Topic; Ritonavir; Thromboembolism; Thrombophilia; Thrombosis | 2020 |
Hospital Pharmacy Compounding against COVID-19 pandemic.
Topics: Administration, Oral; Antiviral Agents; Betacoronavirus; Blood Component Transfusion; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disinfection; Drug Administration Routes; Drug Compounding; Drug Interactions; Drug Stability; Equipment Contamination; Excipients; Forecasting; Home Care Services; Humans; Hydroxychloroquine; Infusions, Intravenous; Lopinavir; Pandemics; Personal Protective Equipment; Pharmacy Service, Hospital; Platelet-Rich Plasma; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Solutions | 2020 |
In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
COVID-19 research: an opinion piece.
Topics: Anti-Retroviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Research; Ritonavir; SARS-CoV-2; Tenofovir; Time Factors | 2020 |
Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.
Topics: Adjuvants, Immunologic; Adult; Aged; Antimalarials; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Interferon beta-1b; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Treatment strategies of hospitalized patients with coronavirus disease-19.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Female; gamma-Globulins; Glucocorticoids; Hospitalization; Humans; Immunologic Factors; Indoles; Interferons; Lopinavir; Male; Middle Aged; Oxygen; Pandemics; Pneumonia, Viral; Respiration, Artificial; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2020 |
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.
Topics: Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Time Factors; Withholding Treatment; Young Adult | 2020 |
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Drug Combinations; Drug Repositioning; Humans; Lopinavir; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Pandemics; Phylogeny; Pneumonia, Viral; Protease Inhibitors; Pyridines; Pyrones; Raltegravir Potassium; Ritonavir; SARS-CoV-2; Sulfonamides; Viral Nonstructural Proteins | 2020 |
Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Betacoronavirus; Central Nervous System Stimulants; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Psychotropic Drugs; Ritonavir; SARS-CoV-2 | 2020 |
Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient.
Topics: Aged; Anemia; Anticoagulants; Anticonvulsants; Antiviral Agents; Betacoronavirus; Calcium Channel Blockers; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Enzyme Inhibitors; Humans; Hydroxychloroquine; Lopinavir; Lymphopenia; Male; Pandemics; Pneumonia, Viral; Posterior Leukoencephalopathy Syndrome; Ritonavir; SARS-CoV-2; Status Epilepticus; Verapamil | 2020 |
Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Risk Assessment; Ritonavir; SARS-CoV-2 | 2020 |
Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Azithromycin; Betacoronavirus; Bicarbonates; Ceftriaxone; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Enoxaparin; Enzyme Inhibitors; Fluid Therapy; Humans; Hydroxychloroquine; Lopinavir; Lung; Male; Pandemics; Pneumonia, Viral; Respiration, Artificial; Rhabdomyolysis; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir.
Topics: Adenosine Monophosphate; Alanine; Coronavirus Infections; COVID-19 Drug Treatment; Data Interpretation, Statistical; Drug Therapy, Combination; Humans; Lopinavir; Randomized Controlled Trials as Topic; Research Design; Ritonavir; Treatment Outcome | 2020 |
Cases of coronavirus disease-2019 in HIV-infected transgender women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Oxazines; Pandemics; Piperazines; Pneumonia, Viral; Pyridones; Ritonavir; SARS-CoV-2; Tenofovir; Transgender Persons | 2020 |
Positive SARS-CoV-2 RNA recurs repeatedly in a case recovered from COVID-19: dynamic results from 108 days of follow-up.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Betacoronavirus; Biomarkers; Cholesterol, HDL; Coronavirus Infections; COVID-19; gamma-Glutamyltransferase; Hospitalization; Humans; Interferon alpha-2; Lopinavir; Male; Methylprednisolone; Pandemics; Pneumonia, Viral; Recurrence; RNA, Viral; SARS-CoV-2; Tomography, X-Ray Computed; Virus Shedding | 2020 |
Imatinib for COVID-19: A case report.
Topics: Adult; Betacoronavirus; Biomarkers; C-Reactive Protein; Coronavirus Infections; COVID-19; Drug Combinations; Female; Humans; Hydroxychloroquine; Imatinib Mesylate; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Protein Kinase Inhibitors; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.
Topics: Adult; Aged; Antirheumatic Agents; Antiviral Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azithromycin; Betacoronavirus; Cohort Studies; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Immunologic Factors; Lopinavir; Lupus Erythematosus, Systemic; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Rheumatic Diseases; Ritonavir; SARS-CoV-2; Severity of Illness Index; Spondylarthropathies | 2020 |
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Topics: Amides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Histone Deacetylase Inhibitors; Humans; Hydroxychloroquine; Immunosuppression Therapy; Kidney Diseases; Long QT Syndrome; Lopinavir; Neoplasms; Pandemics; Pneumonia, Viral; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Hospitalization; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; RNA, Viral; SARS-CoV-2; Virus Shedding | 2020 |
Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles.
Topics: Aged; Antibodies, Neutralizing; Antiviral Agents; Betacoronavirus; Blood Grouping and Crossmatching; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Male; Pandemics; Pneumonia, Viral; Republic of Korea; Ritonavir; SARS-CoV-2; Transfusion-Related Acute Lung Injury | 2020 |
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Biomarkers; C-Reactive Protein; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Drug Administration Schedule; Drug Combinations; Female; Hospitals, University; Humans; Hydroxychloroquine; Length of Stay; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Survival Analysis | 2020 |
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
Topics: Acute Disease; Aged; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Lopinavir; Male; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Respiratory Insufficiency; Ritonavir; SARS-CoV-2; Sulfonamides; Treatment Outcome | 2020 |
Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
Topics: Aged; Coronavirus Infections; COVID-19; Critical Illness; Drug Combinations; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; Standard of Care; Treatment Outcome | 2020 |
COVID-19 & antiepileptic drugs: Should we pay attention?
Topics: Anticonvulsants; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Carbamazepine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Humans; Lopinavir; Pandemics; Phenytoin; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Seizures | 2020 |
Four cases of coronavirus disease 2019 in the early stage of pandemic of South Korea: a single public hospital experience.
Topics: Adult; Coronavirus Infections; COVID-19; Drug Combinations; Female; Humans; Lopinavir; Male; Pandemics; Pneumonia, Viral; Radiography, Thoracic; Ritonavir | 2020 |
Infection of severe acute respiratory syndrome coronavirus 2 in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Indoles; Interferon-alpha; Lopinavir; Lung; Male; Pandemics; Pneumonia, Viral; Radiography, Thoracic; Ritonavir; SARS-CoV-2; Sputum; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Berberine; Betacoronavirus; Chlorocebus aethiops; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cyclosporine; Drug Antagonism; Drug Combinations; Drug Repositioning; Drug Synergism; Humans; Indoles; Lopinavir; Pandemics; Pneumonia, Viral; SARS-CoV-2; Vero Cells | 2020 |
Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients.
Topics: Administration, Oral; Betacoronavirus; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Female; Humans; Intensive Care Units; Lopinavir; Male; Middle Aged; Pandemics; Pharmaceutical Solutions; Pneumonia, Viral; Prospective Studies; Respiration, Artificial; Ritonavir; SARS-CoV-2 | 2020 |
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Child; China; Cohort Studies; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Hospital Mortality; Host Microbial Interactions; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Length of Stay; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Treatment Outcome; Young Adult | 2020 |
Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies.
Topics: Animals; Betacoronavirus; Cells, Cultured; Clinical Trials as Topic; Coculture Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Decidua; Disease Models, Animal; Drug Repositioning; Drug Therapy, Combination; Embryo Implantation; Endometrium; Female; HIV Infections; Humans; Lopinavir; Maternal Exposure; Mice; Pandemics; Placentation; Pneumonia, Viral; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, First; Primary Cell Culture; SARS-CoV-2; Trophoblasts; Vascular Remodeling | 2020 |
[Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir].
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cross-Sectional Studies; Drug Combinations; Drug Interactions; Female; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Risk Factors; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; C-Reactive Protein; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Female; Ferritins; Fibrin Fibrinogen Degradation Products; Hospitalization; Humans; Hydroxychloroquine; Hypertension; Interleukin 1 Receptor Antagonist Protein; L-Lactate Dehydrogenase; Length of Stay; Lopinavir; Lung Diseases, Interstitial; Male; Mortality; Odds Ratio; Pandemics; Pneumonia, Viral; Prospective Studies; Rheumatic Diseases; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Spain | 2020 |
Description of 3 patients with myasthenia gravis and COVID-19.
Topics: Adult; Aged; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Female; Humans; Hydroxychloroquine; Hypertension; Hypothyroidism; Immunocompromised Host; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lopinavir; Male; Myasthenia Gravis; Pandemics; Plasmapheresis; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Case-Control Studies; Cohort Studies; Colchicine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Drug Combinations; Enzyme Inhibitors; Female; Hospitalization; Humans; Hydroxychloroquine; Italy; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Proof of Concept Study; Proportional Hazards Models; Respiratory Distress Syndrome; Ritonavir; SARS-CoV-2; Survival Rate | 2020 |
Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients.
Topics: Adult; Antimalarials; Chloroquine; Chronic Disease; Coronavirus Infections; COVID-19; Drug Combinations; Female; Fever; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; Treatment Outcome; Young Adult | 2020 |
Guidance on the special care of liver or kidney transplant recipients diagnosed with COVID-19
Topics: Adrenal Cortex Hormones; Betacoronavirus; Calcineurin Inhibitors; Contraindications, Drug; Coronavirus Infections; COVID-19; Drug Combinations; Drug Interactions; Humans; Immunosuppression Therapy; Kidney Transplantation; Liver Transplantation; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Transplant Recipients | 2020 |
Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case-control study.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Azithromycin; Betacoronavirus; Case-Control Studies; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Enzyme Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Hydroxychloroquine; Italy; Lopinavir; Male; Middle Aged; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Prognosis; Rehabilitation Centers; Ritonavir; SARS-CoV-2; Spinal Cord Injuries | 2020 |
Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Topics: Animals; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cell Death; Chlorocebus aethiops; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Cytokines; Drug Therapy, Combination; Humans; Inflammation; Lopinavir; Molecular Docking Simulation; Monocytes; Pandemics; Pneumonia, Viral; Protease Inhibitors; Ritonavir; SARS-CoV-2; Vero Cells; Viral Nonstructural Proteins; Virus Replication | 2020 |
Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hospitalization; Humans; Indoles; Interferons; Length of Stay; Lopinavir; Male; Middle Aged; Multiple Organ Failure; Pandemics; Pneumonia, Viral; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2020 |
Coronavirus disease 2019 in patients with HIV in the province of Araba, Basque Country, Spain.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiviral Agents; Betacoronavirus; CD4 Lymphocyte Count; Coinfection; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hydroxychloroquine; Interferon beta-1b; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Protective Factors; Retrospective Studies; Risk Factors; SARS-CoV-2; Severity of Illness Index; Spain; Sustained Virologic Response; Viral Load | 2020 |
[Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality].
Topics: Adrenal Cortex Hormones; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Inpatients; Lopinavir; Male; Pandemics; Pneumonia, Viral; Proportional Hazards Models; Retrospective Studies; Ritonavir; SARS-CoV-2; Spain; Treatment Outcome | 2020 |
Two Cases of SARS-CoV-2 Infection in Pediatric Oncohematologic Patients in Spain.
Topics: Adolescent; Betacoronavirus; Child; Child, Preschool; Coronavirus Infections; COVID-19; Diarrhea; Female; Humans; Kidney Neoplasms; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; Sarcoma, Ewing; SARS-CoV-2; Spain; Wilms Tumor | 2020 |
Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
Topics: Aged; Androgen Antagonists; Androstenes; Anticoagulants; Antineoplastic Agents; Betacoronavirus; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Coronavirus Infections; COVID-19; Disease Progression; Docetaxel; Drug Combinations; Eligibility Determination; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Lopinavir; Male; Oxygen Inhalation Therapy; Palliative Care; Pandemics; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Zoledronic Acid | 2020 |
Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient.
Topics: Aged, 80 and over; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Eryptosis; Erythrocytes; Humans; Lopinavir; Lung; Male; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Autoimmune Diseases; Azithromycin; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Glucocorticoids; Hospitalization; Humans; Hydroxychloroquine; Immunosuppressive Agents; Logistic Models; Lopinavir; Lung Diseases; Lupus Erythematosus, Systemic; Male; Middle Aged; Multivariate Analysis; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Sex Factors; Spain | 2020 |
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Antiviral Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Betacoronavirus; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Comorbidity; Connective Tissue Diseases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Glucocorticoids; Hospitalization; Humans; Hydroxychloroquine; Immunosuppressive Agents; Logistic Models; Lopinavir; Lupus Erythematosus, Systemic; Male; Middle Aged; Obesity; Pandemics; Pneumonia, Viral; Polymyalgia Rheumatica; Prognosis; Rheumatic Diseases; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Sex Factors; Sjogren's Syndrome; Spondylarthropathies | 2020 |
Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia.
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Bradycardia; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Heart Rate; Humans; Intensive Care Units; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Prospective Studies; Risk Assessment; Risk Factors; Ritonavir; SARS-CoV-2; Time Factors; Treatment Outcome | 2020 |
Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Combinations; Drug Repositioning; Drug Therapy, Combination; Epidemiologic Research Design; Humans; Interferon beta-1b; Lopinavir; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Female; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pulmonary Fibrosis; Radiography; Retrospective Studies; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report.
Topics: Adult; Antiviral Agents; Betacoronavirus; Cardiotonic Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Combinations; Echocardiography; Humans; Lopinavir; Male; Pandemics; Plasma Exchange; Pneumonia, Viral; Respiration, Artificial; Respiratory Distress Syndrome; Ritonavir; SARS-CoV-2; Shock, Cardiogenic; Takotsubo Cardiomyopathy | 2020 |
Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
Topics: Aged; Anti-Infective Agents; Azithromycin; Betacoronavirus; Biomarkers; Coronavirus Infections; COVID-19; Disease Progression; Drug Combinations; Female; Humans; Hydroxychloroquine; Intensive Care Units; Long QT Syndrome; Lopinavir; Lymphocytes; Male; Middle Aged; Neutrophils; Pandemics; Pneumonia, Viral; Prognosis; Proportional Hazards Models; Retrospective Studies; Ritonavir; SARS-CoV-2; Treatment Outcome; Troponin I | 2020 |
Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.
Topics: Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Intensive Care Units; Jaundice; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Prospective Studies; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Standard of Care | 2020 |
Signal amplification by reversible exchange for COVID-19 antiviral drug candidates.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Discovery; Humans; Lopinavir; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib.
Topics: Aged; Anaplastic Lymphoma Kinase; Anti-HIV Agents; Betacoronavirus; Carbazoles; Carcinoma, Non-Small-Cell Lung; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Lung; Lung Neoplasms; Male; Masks; Noninvasive Ventilation; Pandemics; Piperidines; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Viral exanthema as manifestation of SARS-CoV-2 infection: A case report.
Topics: Administration, Topical; Adult; Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Combinations; Exanthema; Female; Glucocorticoids; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Symptom Assessment; Treatment Outcome | 2020 |
[Skin manifestations associated with the new coronavirus SARS-CoV-2 disease].
Topics: Anti-Inflammatory Agents; Antiviral Agents; Benzimidazoles; Betacoronavirus; Betamethasone; Causality; Coronavirus Infections; COVID-19; Drug Eruptions; Drug Therapy, Combination; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Prednisone; Ritonavir; SARS-CoV-2; Skin Diseases, Viral | 2020 |
Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Guanidines; Hemodiafiltration; Humans; Hydroxychloroquine; Japan; Lopinavir; Male; Pandemics; Pneumonia, Viral; Respiratory Insufficiency; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
[Clinical characteristics of liver damage in 30 patients with severe coronavirus disease 2019 in Sichuan area].
Topics: Aged; Aged, 80 and over; Antiviral Agents; China; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Liver Diseases; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; Severity of Illness Index; Treatment Outcome | 2020 |
SARS-CoV-2 and hepatitis.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Betacoronavirus; Chemical and Drug Induced Liver Injury; Chloroquine; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Diagnosis, Differential; Drug Combinations; Hepatitis, Viral, Human; Humans; Liver; Liver Function Tests; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Data Mining; Databases, Genetic; Drug Therapy, Combination; Gene Regulatory Networks; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Toxicogenetics | 2020 |
Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Double-Blind Method; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Pneumonia, Viral; Registries; Ritonavir; SARS-CoV-2; Single-Blind Method; Stem Cell Transplantation | 2020 |
The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Indoles; Lopinavir; Medicine, Chinese Traditional; Methylprednisolone; Middle Aged; Moxifloxacin; Noninvasive Ventilation; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Qi; Ritonavir; SARS-CoV-2 | 2020 |
Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Chloroquine; Coronavirus Infections; COVID-19; Cuba; Drug Therapy, Combination; Female; Humans; Infant; Interferon alpha-2; Interferon-alpha; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Prospective Studies; Ritonavir; SARS-CoV-2; Young Adult | 2020 |
Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.
Topics: Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
COVID-19 outbreak in Italy: Clinical-radiological presentation and outcome in three oncologic patients.
Topics: Aged; Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Carcinoma, Squamous Cell; Coronavirus Infections; COVID-19; Disease Outbreaks; Drug Therapy, Combination; Esophageal Neoplasms; Fatal Outcome; Humans; Hydroxychloroquine; Italy; Lopinavir; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Audio Interview: Covid-19 and the President.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Federal Government; Glucocorticoids; Government Employees; HIV Protease Inhibitors; Humans; Hypoxia; Immunization, Passive; Lopinavir; Oxygen Inhalation Therapy; Pandemics; Patient Acuity; Pneumonia, Viral; Risk Assessment; SARS-CoV-2; United States; Virus Replication | 2020 |
Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation.
Topics: Betacoronavirus; Binding Sites; Biophysical Phenomena; Catalytic Domain; Computational Biology; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Darunavir; Drug Repositioning; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Dynamics Simulation; Nelfinavir; Pandemics; Pneumonia, Viral; Ritonavir; Saquinavir; SARS-CoV-2; Viral Nonstructural Proteins | 2020 |
[Adverse effects of lopinavir/ritonavir in critically ill patients with COVID-19].
Topics: Adult; Aged; Argentina; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Cytochrome P-450 CYP3A Inhibitors; Female; Humans; Lopinavir; Male; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
The Economic and Public Health Imperatives Around Making Potential Coronavirus Disease-2019 Treatments Available and Affordable.
Topics: Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Public Health; Ritonavir; SARS-CoV-2 | 2020 |
Early triple antiviral therapy for COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Interferon beta-1b; Lopinavir; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Early triple antiviral therapy for COVID-19 - Authors' reply.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Interferon beta-1b; Lopinavir; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
First patient management of COVID-19 in Changsha, China: a case report.
Topics: Betacoronavirus; China; Coronavirus Infections; Cough; COVID-19; COVID-19 Drug Treatment; Female; Fever; Glucocorticoids; HIV Protease Inhibitors; Humans; Interferon alpha-2; Lopinavir; Lung; Middle Aged; Pandemics; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Aged; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Humans; Hydroxychloroquine; Inflammation; Intensive Care Units; Interleukin-10; Interleukin-6; Interleukin-8; Italy; Leukocytes; Leukocytes, Mononuclear; Lopinavir; Lung; Lymphocytes; Macrophages, Alveolar; Male; Microscopy, Electron, Transmission; Middle Aged; Neutrophils; Pandemics; Pneumonia, Viral; Prognosis; Prospective Studies; Respiration, Artificial; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Survival Rate; Virion | 2020 |
COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with?
Topics: Adalimumab; Adult; Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Azathioprine; Betacoronavirus; Biological Therapy; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Combinations; Drug Therapy, Combination; Humans; Lopinavir; Male; Methotrexate; Oseltamivir; Pandemics; Pneumonia, Viral; Prednisolone; Ritonavir; SARS-CoV-2 | 2020 |
Development of A MERS-CoV Replicon Cell Line for Antiviral Screening.
Topics: Antiviral Agents; Cell Line; Coronavirus Infections; Drug Evaluation, Preclinical; Humans; Lopinavir; Middle East Respiratory Syndrome Coronavirus; Replicon | 2021 |
Reply Letter - "Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis".
Topics: Antiviral Agents; Child; Coronavirus; Coronavirus Infections; Humans; Lopinavir; Ritonavir | 2021 |
Comment on safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis.
Topics: Antiviral Agents; Child; Coronavirus; Coronavirus Infections; Humans; Lopinavir; Ritonavir | 2021 |
Combining subsidiary and synchronous approaches for concurrent spectrofluorimetric assurance of lopinavir and ritonavir in tablets utilized in convention for treatment of coronavirus infection (COVID-19) and biological fluids.
Topics: Coronavirus Infections; COVID-19 Drug Treatment; Drug Combinations; Humans; Lopinavir; Ritonavir; SARS-CoV-2; Spectrometry, Fluorescence; Tablets | 2021 |
Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.
Topics: Adult; Aged; Antiviral Agents; Coronavirus Infections; Drug-Related Side Effects and Adverse Reactions; Female; Health Personnel; Humans; Incidence; Lopinavir; Male; Post-Exposure Prophylaxis; Retrospective Studies; Ribavirin; Ritonavir; Young Adult | 2019 |
Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen.
Topics: Antiviral Agents; Coronavirus Infections; Drug Combinations; Drug Therapy, Combination; Greece; Humans; Lopinavir; Male; Middle East Respiratory Syndrome Coronavirus; Phylogeny; Respiratory Tract Infections; Ribavirin; Ritonavir; Viremia; Virus Shedding | 2014 |
Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset.
Topics: Animals; Antiviral Agents; Callithrix; Coronavirus Infections; Disease Models, Animal; Drug Repositioning; Interferon-beta; Lopinavir; Male; Middle East Respiratory Syndrome Coronavirus; Ritonavir; Survival Analysis; Treatment Outcome; Viral Load | 2015 |
Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.
Topics: Antiviral Agents; Coronavirus Infections; Drug Therapy, Combination; Humans; Interferon-alpha; Lopinavir; Male; Middle Aged; Middle East Respiratory Syndrome Coronavirus; Republic of Korea; Ribavirin; Ritonavir | 2016 |